Opinion|Videos|June 6, 2025
Addressing Critical Gaps in the Management of NSCLC and the Importance of the Next Wave of Treatment Advances
Author(s)Lauren Ledbetter, PharmD, BCOP
A panelist discusses how emerging research in non–small cell lung cancer (NSCLC) is focused on determining the most effective neoadjuvant/adjuvant approaches combining chemotherapy with immunotherapy, addressing tumor heterogeneity through potential combinations of targeted therapies, and investigating mechanisms of immunotherapy nonresponse to improve patient outcomes.
Advertisement
Episodes in this series
Current Research Challenges
- Early-stage NSCLC:
- Multiple FDA approvals for neoadjuvant/adjuvant chemoimmunotherapy; awaiting mature data to establish optimal approach
- Tumor heterogeneity: Multiple targetable mutations often present; no current data on combining targeted therapies
- Immunotherapy nonresponders: Research needed to understand mechanisms of nonresponse and identify additional targets
- Focus on minimizing toxicity exposure when benefit cannot be guaranteed
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Yes, COVID-19 Is Still a Big Deal. Pharmacy Is the Tip of the Spear (and Needle)
2
FDA Fast Tracks First-in-Class TNFR2 Antibody as Chemotherapy-Free Strategy for Platinum-Resistant Ovarian Cancer
3
Beat the Heat: 10 Common Medication Culprits Causing Heat Intolerance
4
The Inflation Reduction Act and Oncology Drug Pricing: What Pharmacists Need to Know
5